ANDAORALTABLET
Approved
Apr 2016
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
AMLODIPINE BESYLATE AND VALSARTAN (amlodipine and valsartan) by Aurobindo Pharma is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 2016.
Drug data last refreshed 19h ago
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
Started Jan 2007
1,134 enrolled
Hypertension
Company
Worked on AMLODIPINE BESYLATE AND VALSARTAN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.